NasdaqGM - Nasdaq Real Time Price ? USD Ikena Oncology, Inc. (IKNA) Follow Compare 1.7300 +0.0300 (+1.76%) At close: November 21 at 4:00 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations 3 US Penny Stocks With Market Caps Over $40M To Consider As the U.S. stock market takes a breather following a post-election rally, investors are keenly observing opportunities that might arise in different sectors. Penny stocks, despite their somewhat outdated name, remain relevant as they often represent smaller or newer companies with potential for growth. With strong financial foundations and solid fundamentals, these stocks can offer valuable opportunities for those willing to explore beyond the well-trodden paths of larger firms. Simply Wall St. ? 8 days ago IKNA +1.76% MNOV RLYB -0.55% Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) Ikena Oncology ( NASDAQ:IKNA ) Third Quarter 2024 Results Key Financial Results Net loss: US$10.2m (loss narrowed by... Simply Wall St. ? 12 days ago IKNA +1.76% Ikena Oncology Reports Third Quarter 2024 Financial Results Strong financial position with $138 million in cash and investments at close of third quarterBOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the third quarter ended September 30, 2024, and provided an update regarding its ongoing activities. Pipeline and Corporate Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared GlobeNewswire ? 14 days ago IKNA +1.76% Ikena Oncology Reports Second Quarter 2024 Financial Results Strong financial position with $145 million in cash and investments at close of second quarterBOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced financial results for the second quarter ended June 30, 2024, and provided an update regarding its ongoing activities. Pipeline Updates Dose escalation in the Phase 1 study of IK-595 in patients with RAS and RAF mutant cancers continues, with multiple cohorts having cleared their safety eval GlobeNewswire ? 3 months ago IKNA +1.76% Best Momentum Stocks to Buy for July 12th IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024. Zacks ? 4 months ago IKNA +1.76% AVAH VEL It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year Key Insights Ikena Oncology's Annual General Meeting to take place on 7th of June CEO Mark Manfredi's total... Simply Wall St. ? 5 months ago IKNA +1.76% UPDATE – Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development GlobeNewswire ? 5 months ago IKNA +1.76% Ikena Oncology Announces Strategic Update Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options to maximize shareholder value BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) today announced discontinuation of the clinical IK-930 program, the Company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development GlobeNewswire ? 5 months ago IKNA +1.76% Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provi GlobeNewswire ? 6 months ago IKNA +1.76% Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will present a corporate overview at the Stifel 2024 Targeted Oncology Forum, taking place virtually from April 16-17, 2024. The Company will also be holding one-on-one investor meetings at the event. Details are as follows: Date: Tuesday, April 16, 2024Time: 2:00 p.m. ETWebcast GlobeNewswire ? 7 months ago IKNA +1.76% Ikena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag Ikena Oncology ( NASDAQ:IKNA ) Full Year 2023 Results Key Financial Results Net loss: US$68.2m (flat on FY 2022... Simply Wall St. ? 8 months ago IKNA +1.76% Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including additional data from EHE patients in dose escalation and initial mesothelioma patient data IK-595 Phase I dose escalation study currently recruiting targeted patients Closed 2023 in a strong financial position with $175M; runway into 2H 2026 BOSTON, March 12, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”) GlobeNewswire ? 8 months ago IKNA +1.76% Ikena Oncology to Participate in TD Cowen 44th Annual Health Care Conference BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in a targeted oncology panel at the TD Cowen 44th Annual Health Care Conference, taking place March 4-6, 2024, in Boston, MA. The Company will also be holding one-on-one investor meetings at the conference. Details on the panel can be found below: Ikena Panelist: GlobeNewswire ? 8 months ago IKNA +1.76% Ikena Oncology Appoints Caroline Germa, M.D. as Chief Medical Officer Caroline Germa, M.D., an accomplished senior executive and medical oncologist, brings over 25 years of pharmaceutical and drug development expertise Dr. Germa will drive clinical development strategy and oversee the execution of targeted oncology programs, IK-930 and IK-595 Sergio Santillana, M.D., MSc., MBA resigned from current role as Chief Medical Officer BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new GlobeNewswire ? 8 months ago IKNA +1.76% Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround The heavy selling pressure might have exhausted for Ikena Oncology, Inc. (IKNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. Zacks ? 9 months ago IKNA +1.76% Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround Ikena Oncology, Inc. (IKNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Zacks ? 9 months ago IKNA +1.76% Ikena Oncology to lay off 35% of staff The cancer drugmaker is one of about a dozen biotechs that have announced workforce reductions so far in 2024. BioPharma Dive ? 9 months ago IKNA +1.76% Ikena Oncology Outlines Key Priorities and Provides Corporate Updates IK-930 optimized formulation now in the clinic; on track to deliver additional monotherapy data in 2H 2024 IK-595 first cohort treated and cleared safety evaluation window Focused execution on core targeted oncology clinical programs; organizational reallocation of resources from exploratory discovery to clinical development of IK-930 and IK-595 Ended 2023 in strong financial position with approximately $175 million in cash; runway extended into 2H 2026 BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GlobeNewswire ? 9 months ago IKNA +1.76% Performance Overview Trailing total returns as of 11/21/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return IKNA S&P 500 YTD -12.18% +24.72% 1-Year +1.17% +30.82% 3-Year -88.80% +26.62%
